We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
NXTMH.HE

Price
7.98
Stock movement up
+0.20 (2.57%)
Company name
Nexstim Oyj
Exchange
(HE
,
Currency
EUR
)
Sector
Healthcare >
Medical Devices
Market cap
57.15M
Ent value
62.74M
Price/Sales
7.86
Price/Book
20.15
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
38.00
PEG
-
EPS growth
-49.81%
1 year return
238.14%
3 year return
14.54%
5 year return
55.07%
10 year return
-33.78%
Last updated: 2025-04-12

DIVIDENDS

NXTMH.HE does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales7.86
Price to Book20.15
EV to Sales8.63

FINANCIALS

Per share

Loading...
Per share data
Current share count7.16M
EPS (TTM)-0.12
FCF per share (TTM)-0.33

Income statement

Loading...
Income statement data
Revenue (TTM)7.27M
Gross profit (TTM)7.42M
Operating income (TTM)-704.05K
Net income (TTM)-789.09K
EPS (TTM)-0.12
EPS (1y forward)0.21

Margins

Loading...
Margins data
Gross margin (TTM)102.12%
Operating margin (TTM)-9.69%
Profit margin (TTM)-10.86%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.45M
Net receivables2.81M
Total current assets5.94M
Goodwill0.00
Intangible assets2.92M
Property, plant and equipment347.29K
Total assets9.88M
Accounts payable650.27K
Short/Current long term debt0.00
Total current liabilities3.44M
Total liabilities7.05M
Shareholder's equity2.84M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-853.91K
Capital expenditures (TTM)1.59M
Free cash flow (TTM)-2.22M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-27.82%
Return on Assets-7.98%
Return on Invested Capital-15.12%
Cash Return on Invested Capital-42.60%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open8.00
Daily high8.04
Daily low7.80
Daily Volume8K
All-time high705.72
1y analyst estimate4.00
Beta1.16
EPS (TTM)-0.12
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
NXTMH.HES&P500
Current price drop from All-time high-98.87%-12.89%
Highest price drop-99.91%-56.47%
Date of highest drop25 Mar 20209 Mar 2009
Avg drop from high-89.07%-11.07%
Avg time to new high365 days12 days
Max time to new high2346 days1805 days
COMPANY DETAILS
NXTMH.HE (Nexstim Oyj) company logo
Marketcap
57.15M
Marketcap category
Small-cap
Description
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's navigated transcranial magnetic stimulation (nTMS) technology utilizes 3D navigation for providing accurate and personalized targeting of the TMS to the specific areas of the brain. It also offers Navigated Brain Therapy system, a navigated brain therapy system for the treatment of major depressive disorder (MDD) and chronic neuropathic pain; and Navigated Brain Stimulation (NBS) system, a navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. The company primarily markets and sells its diagnostics systems to universities and teaching hospitals. Nexstim Plc was incorporated in 2000 and is headquartered in Helsinki, Finland.
Employees
39
Investor relations
-
CEO
Country
Finland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Nexstim Oyj (FRA:5NX) reports a 21% sales increase and positive EBITDA, driven by the successful launch of the NBS 6 therapy system and a pivotal partnership with Brainlab.
March 1, 2025
CAMBRIDGE, Mass., January 15, 2025--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...
January 15, 2025
Nexstim Oyj (FRA:5NX) reports a 27% increase in net sales and significant improvements in operating results for the first half of 2024.
October 9, 2024
Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS Syst...
October 2, 2024
Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospita...
September 27, 2024
Press release, Helsinki, 3 September 2024 at 9 AM (EEST) New European Customer Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 fr...
September 3, 2024
Company announcement, Helsinki, August 16, 2024 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED) NEXSTIM CONTINUED TO GROW AND IMPROVED ITS PROFITABILITY IN THE FIRST ...
August 16, 2024
Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") will publish its half-yearly report for the six...
August 13, 2024
Press release, Helsinki, 10 July 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from New European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS Sy...
July 10, 2024
Press release, Helsinki, 1 July 2024 at 11:30 AM (EEST) US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received a...
July 1, 2024
Next page